Novo Nordisk shares fell up to 7% after CEO Mike Doustdar announced a $23 billion sales target and five new blockbuster drugs

BusinessSep 21 at 4:14 AM – Sep 21 at 5:33 AM3 outlets

Bloomberg

Novo Plunges as Investors Seek More Robust Sales Targets Sep 21 at 5:26 AM

Novo Touts Future Blockbuster Launches, Disappointing Investors Opens in new window seen Sep 21 at 4:38 AM

Novo Touts Future Blockbuster Launches, Disappointing Investors Sep 21 at 4:14 AM

CNBC

Novo stock falls as much as 7% despite $23 billion sales target for blockbuster obesity drugs Sep 21 at 4:47 AM

STAT

STAT+: With new strategy, Novo outlines plans for obesity, direct-to-consumer work Sep 21 at 5:33 AM